A developer of innovative medications for serious central nervous system illnesses.

Adeona enters agreement to begin proprietary zinc-based therapy Stage IIb trial in ALS Adeona Pharmaceuticals, Inc. , a developer of innovative medications for serious central nervous system illnesses, announced today that it provides extended its pipeline of proprietary zinc-based therapies to include a well planned Phase IIb medical trial of patients experiencing amyotrophic lateral sclerosis , also referred to as Lou Gehrig’s Disease drug information . Preparations are underway to evaluate the basic safety and efficacy of the Company’s proprietary drug applicants, AEN-100, a gastroretentive, sustained-release zinc-centered tablet, and AEN-200, a copper tablet, in a multi-center, double-blind, placebo-controlled scientific trial in ALS patients intended to be executed under an Investigational New Drug application.